- Home
- RARE vs FA Comparison
RARE vs FA Comparison
Compare RARE & FA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- FA
- Stock Information
- Founded
- RARE 2010
- FA 2003
- Country
- RARE United States
- FA United States
- Employees
- RARE N/A
- FA N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- FA Business Services
- Sector
- RARE Health Care
- FA Consumer Discretionary
- Exchange
- RARE Nasdaq
- FA Nasdaq
- Market Cap
- RARE 3.5B
- FA 3.0B
- IPO Year
- RARE 2014
- FA 2021
- Fundamental
- Price
- RARE $36.01
- FA $16.84
- Analyst Decision
- RARE Strong Buy
- FA Hold
- Analyst Count
- RARE 15
- FA 6
- Target Price
- RARE $90.53
- FA $20.75
- AVG Volume (30 Days)
- RARE 1.1M
- FA 1.2M
- Earning Date
- RARE 07-31-2025
- FA 08-07-2025
- Dividend Yield
- RARE N/A
- FA N/A
- EPS Growth
- RARE N/A
- FA N/A
- EPS
- RARE N/A
- FA N/A
- Revenue
- RARE $590,689,000.00
- FA $1,045,377,000.00
- Revenue This Year
- RARE $18.94
- FA $82.98
- Revenue Next Year
- RARE $28.93
- FA $6.54
- P/E Ratio
- RARE N/A
- FA N/A
- Revenue Growth
- RARE 33.46
- FA 37.98
- 52 Week Low
- RARE $29.59
- FA $12.32
- 52 Week High
- RARE $60.37
- FA $20.79
- Technical
- Relative Strength Index (RSI)
- RARE 51.86
- FA 47.72
- Support Level
- RARE $36.03
- FA $15.74
- Resistance Level
- RARE $37.74
- FA $16.92
- Average True Range (ATR)
- RARE 1.46
- FA 0.58
- MACD
- RARE -0.01
- FA -0.19
- Stochastic Oscillator
- RARE 26.56
- FA 34.48
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About FA First Advantage Corporation
First Advantage Corp is a provider of employment background screening and verification solutions. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. Maximum revenue is generated from the First Advantage Americas segment, which performs various background checks and compliance services across all phases of the workforce lifecycle, from pre-onboarding services to post-onboarding and ongoing monitoring services, covering employees, contractors, contingent workers, tenants, and drivers. The company delivers solutions across multiple industry verticals in the United States, Canada, and Latin America. Geographically, it derives key revenue from the United States.